Published in Acta Neurol Belg on April 04, 2012
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol (2009) 6.96
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology (2013) 2.98
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity (2010) 2.54
Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation (2002) 2.49
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage (2011) 2.31
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke (2002) 1.94
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med (2011) 1.72
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation (2004) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Boxing-acute complications and late sequelae: from concussion to dementia. Dtsch Arztebl Int (2010) 1.59
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest (2006) 1.43
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol (2010) 1.35
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation (2012) 1.29
Spatiotemporal reconfiguration of large-scale brain functional networks during propofol-induced loss of consciousness. J Neurosci (2012) 1.28
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Simultaneous electroencephalographic and functional magnetic resonance imaging indicate impaired cortical top-down processing in association with anesthetic-induced unconsciousness. Anesthesiology (2013) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 1.24
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One (2011) 1.13
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun (2009) 1.12
The role of antibodies in multiple sclerosis. Biochim Biophys Acta (2010) 1.12
Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol (2010) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis. Arch Neurol (2003) 1.10
The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol (2010) 1.09
Transient ischemic attack and stroke can be differentiated by analyzing early diffusion-weighted imaging signal intensity changes. Stroke (2004) 1.09
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Acyclovir resistance in herpes simplex encephalitis. Ann Neurol (2010) 1.06
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun Rev (2011) 1.02
Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol (2009) 1.01
TNF-alpha induced NFκB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine (2011) 1.01
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet (2008) 0.98
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation (2011) 0.97
Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci (2007) 0.96
Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ (2010) 0.96
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler (2013) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res (2009) 0.95
Prognostic value of the ABCD2 score beyond short-term follow-up after transient ischemic attack (TIA)--a cohort study. BMC Neurol (2010) 0.95
Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother (2015) 0.94
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One (2010) 0.93
EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother (2010) 0.93
Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology (2014) 0.93
Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Mult Scler (2011) 0.93
Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des (2012) 0.92
The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol (2008) 0.91
Gene expression profiles derived from single cells in human postmortem brain. Brain Res Brain Res Protoc (2004) 0.91
A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics (2002) 0.91
Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol (2007) 0.91
White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI. Mult Scler (2013) 0.90
Autosomal dominant congenital nystagmus is not linked to 6p12, 7p11, and 15q11 in a German family. Am J Ophthalmol (2004) 0.90
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89
Enriched CD161high CCR6+ γδ T cells in the cerebrospinal fluid of patients with multiple sclerosis. JAMA Neurol (2013) 0.89
Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun (2010) 0.88
Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. Eur J Immunol (2007) 0.88
High throughput analysis of TCR-beta rearrangement and gene expression in single T cells. Lab Invest (2006) 0.88
Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Ann Neurol (2014) 0.88
Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol (2006) 0.87
Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler (2007) 0.87
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol (2005) 0.86
Depressive symptoms and the risk of ischemic stroke in the elderly--influence of age and sex. PLoS One (2012) 0.86
JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog (2014) 0.86
Accelerated aging of the putamen in men but not in women. Neurobiol Aging (2007) 0.86
Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammation. J Neuroimmunol (2006) 0.86